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Hemophagocytic lymphohistiocytosis is a potentially fatal disease characterized by excessive macrophage and
lymphocyte activity. Patients can be affected following immune activation after an oncologic, autoimmune or
infectious trigger. An associated gene mutation may be found which impairs cytolytic lymphocyte function. We
describe a pediatric case of hemophagocytic lymphohistiocytosis with a novel mutation of MUNC 13–4 whose
diagnosis was confounded by concurrent immunosuppression. Clinical reassessment for hemophagocytic
lymphohistiocytosis is necessary in persistently febrile patients with laboratory derangements in the setting of
immunosuppressive agent exposure.
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Hemophagocytic lymphohistiocytosis (HLH) is a clinical
syndrome of abnormal immune activation causing excess
inflammation. There is increased ectopic migration and
proliferation of T cells, tissue infiltration by activated
macrophages (histiocytes), hyper-activation of lympho-
cytes, and prolonged release of pro-inflammatory cyto-
kines [1]. This leads to uncontrolled inflammation
manifesting as fever, cytopenias and organ dysfunction.
The syndrome is fatal without prompt symptom recog-
nition and treatment.
Primary HLH, also known as familial HLH, is often
considered a pediatric disease. Affected individuals have
mutations in genes leading to impaired lytic activity of
lymphocytes, including NK cells and cytotoxic T lym-
phocytes [2]. These individuals are at risk of developing
HLH. Mutations are inherited in an autosomal recessive
pattern, but can also result from de novo mutations,
making family history less reliable for diagnosis.* Correspondence: garrettjp@email.chop.edu
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reproduction in any medium, provided the origAcquired HLH, also known as secondary HLH, occurs
more commonly in adults. Nonetheless, it is also
described in children. There are presently no identifiable
genetic mutations linked to this phenotype. Currently,
secondary HLH is attributed to an abnormal immune
response triggered by an infectious, oncologic or auto-
immune etiology. As such, other names for secondary HLH
include Virus-Associated Hemophagocytic Syndrome and
Malignancy-Associated Hemophagocytic Syndrome [3].
The diagnosis of HLH is based on clinical criteria. The
most recent diagnostic guidelines were revised in 2004
[4]. HLH is diagnosed if either a molecular diagnosis
consistent with HLH is made, or five of the eight follow-
ing diagnostic criteria are met: 1.) fever; 2.) splenomeg-
aly; 3.) cytopenias affecting at least two of three lineages
in the peripheral blood (haemoglobin <90 g/L, platelets
<100× 109/L, or neutrophils <1× 109/L); 4.) hypertrigly-
ceridemia (fasting triglycerides≥ 3 mmol/L (≥ 265 mg/
dL)) and/or hypofibrinogenemia (fibrinogen≤ 1.5mg/dL);
5.) hemophagocytosis in bone marrow, spleen, or lymph
nodes (excluding signs of malignancy); 6.) low or absent
NK-cell activity; 7.) hyperferritinemia (ferritin >500 μg/L);
and 8.) high levels of sIL-2R (sIL-2R≥ 2400 U/ml).Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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mutation in MUNC 13–4 whose diagnosis of HLH was
confounded by low dose treatment with immunosup-
pressive agents thereby complicating her clinical picture.
Case presentation
Our patient is a 3 year-old female who was previously
healthy. Four months prior to hospitalization she began
experiencing fatigue, recurrent fevers, progressive
muscle weakness, and behavioral changes. The week
prior to admission, she had decreased urine output,
increased abdominal girth and respiratory distress. She
was admitted to a community hospital for possible pneu-
monia. After 3 days, she was transferred to a tertiary cen-
ter for oncologic assessment. There, her physical
examination was concerning for a tender right axillary
lymph node and hepatosplenomegaly. A chest radiograph
demonstrated diffuse airspace opacities. PCR studies iden-
tified both rhinovirus and mycoplasma in nasal pharyngeal
swabs. Twenty-four hours after arrival she developed
hypoxemic respiratory failure requiring tracheal intubation
and mechanical ventilation. This was complicated by an as-
piration event and subsequent cardiopulmonary arrest, re-
quiring resuscitation. Multiple subspecialties convened to
facilitate an underlying diagnosis. HLH was considered
given her hepatosplenomegaly, cytopenias, elevated CRP
and normal ESR in the context of documented infection.
Table 1 presents key HLH laboratory markers ordered at
onset and their results. MAS, possibly associated with sJIA,
was also considered despite the absence of arthritis, be-
cause of an intermittent, pink, net-like rash in the preced-
ing weeks. Bone marrow evaluation was performed soonTable 1 Laboratory values meeting HLH diagnostic criteria fo
HLH diagnostic criteria
Timing relative to anakinra trial Admission to prior to anakinra
Cytopenia in≥2 cell lines
Haemoglobin< 9g/dL (90g/L) WNL
Platelet< 100× 109/L 60
Absolute neutrophil count < 1000 / μL 924
Hypertriglyceridemia and/orHypofibrinogenemia
Fasting triglyceride≥ 265 mg/dL) -
Fibrinogen< 150 mg/dL 127
Ferritin≥500ng/mL (500µg/L) 905
sCD25≥2400μg/mL -




Hemophagocytosis in bone marrow “some”
-: laboratory value not measured; d: day from start of anakinra; NK: natural killer; W
a LU20 NK: Patient NK cells were cultured with radioisotope-labeled tumor cells. Fun
correction for patient peripheral blood mononuclear cell % NK.
b CD107a: Mononuclear cells from peripheral blood were stimulated with K562 targ
was detected by flow cytometry.after her admission and demonstrated only rare hemopha-
gocytes, similar to those seen in children with an under-
lying infection [5].
Over the next month our patient continued to be
dependent upon mechanical ventilation and developed
acute respiratory distress syndrome (ARDS). Other com-
plications included respiratory syncitial virus (RSV) in-
fection and central line-related deep vein thrombosis
requiring a six-week course of heparin sulfate. A brain
MRI showed diffuse patchy white matter lesions most
prominent in the right frontal lobe, suggestive of ische-
mia. Concern arose for adrenal insufficiency and she
received several courses of stress dose corticosteroids
with intermittent tapers. Intermittent episodes of fever
and worsening cytopenias continued over the next month
and HLH, possibly MAS, remained a consideration. For
this reason an 18-day trial of anakinra was undertaken.
However, fevers continued and abnormalities in liver
enzymes along with hematologic abnormalities continued.
At this point, genetic testing results became available
and identified two mutations in MUNC13-4: a known
pathogenic mutation 1389(+1) G>A, a splice donor
site of intron 15, and a second previously unidentified
mutation, 1847 A>G. This second mutation was
located in the splice donor site of exon 20, and the A
>G change at this position would likely cause splicing
error. It was unclear if this represented a compound
heterozygous mutation or if the two variants were on
a single chromosome. Parental testing was initiated.
Given the genetic results and her persistent symptoms,
the laboratory and bone marrow evaluations for HLH
were reconsidered.und prior to, during and after trial of anakinra
Patient laboratory values
During anakinra (day from start of anakinra) One week after anakinra
8.8 (d2); Nadir 5.2 (d16) WNL
26 (d 16) 13-21
700 (d17) 48-153
802 (d16) 423, 577, 726
WNL -
629 (d15) 4814, 7597
42,140 (d17) -
37.4 (d4) -
7 % (d17) -
“numerous”
NL: within normal limits.
ctional NK cell activity measured by quantifying released isotope after
et cells to induce degranulation. Six hours post incubation, CD107a expression
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anakinra use were evaluated (Tables 1 and 2). When
compared to the initial assessment, there was subse-
quent marked reduction in natural killer (NK) cell func-
tion, CD107a upregulation and an elevation in soluble
IL-2 (soluble CD25) receptor. Importantly, a drop in
ANC (Figure 2a) and platelet count (Figure 2b) was
identified during the end of the anakinra trial. Children
with active HLH have been noted to have elevated white
cell and platelet counts initially that decrease over time
[6], as illustrated in our case. As a confounding feature,
however, cytopenia is an uncommon but known side ef-
fect of anakinra. It is thus possible that addition of ana-
kinra in our patient, with underlying MUNC 13–4
mutations, magnified the drop in platelet count and
ANC that would have been seen with HLH alone. In
addition, when ferritin was measured on the 15th day of
anakinra therapy, the level was 629 ng/mL (above the
aforementioned acceptable limit of 500 ng/mL), whereas
one day after anakinra treatment was terminated, the
ferritin level increased to 7129 ng/mL (Figure 2c). IL-1
is known to increase the synthesis of ferritin subunits
in vitro [7]. We hypothesize, therefore, that anakinra ad-
ministration inhibited the surge of ferritin that would
have otherwise been identified in association with clin-
ical progression of HLH.
A repeat bone marrow biopsy and the first and second
bone biopsies were compared (Figure 2 and Figure 3).
The first and second bone marrow biopsies were also
critically compared (Figure 3). The latter showing a sub-
stantive increase in hematophagocytes compared to the
former. In addition, a lumbar puncture showed an ele-
vated protein level (109 mg/dL) with a lymphocyticTable 2 Laboratory values meeting HLH diagnostic
criteria found prior to, during and after trial of anakinra









Cytopenia in≥2 cell lines
Anemia No Yes No
Thrombocytopenia Yes Yes Yes




Hypofibrinogenemia Yes No -
Hyperferritinemia Yes Yes Yes
Elevated sCD25 - Yes -
NK cell activity
LU20 NK reduced markedly reduced -




-: laboratory value not measured; NK: natural killer.pleocytosis (12 WBC with 100% lymphocytes). These find-
ings suggested central nervous system HLH involvement.
Table 1: Initial laboratory values
Table 2: Evolution of laboratory values
Figure 1: Illustration of key laboratory value evolution
Figure 2: Bone marrow aspirate; Wright stain post-
anakinra
Figure 3: CD 163 immunohistochemical stain of bone
marrow biopsy
With this collective evidence, the HLH-2004 clinical
protocol was initiated [4]. Our patient was treated with
dexamethasone and etoposide. Cyclosporine was not ini-
tially utilized because of concern of abnormal kidney
and liver function, but was added later as she improved.
Parental genetic testing was performed in order to de-
termine if her case was likely primary HLH with familial
genetic etiology. Testing confirmed that each parent car-
ried one of the MUNC 13-4 mutations found in the pa-
tient. One parent possessed the novel variant identified
while the other carried the known splice site mutation
thus defining the patient as a compound UNC13D het-
erozygote consistent with FHL3.
Our patient was hospitalized for almost 4 months
prior to transfer to a rehabilitation institution. She
received a tracheostomy tube prior to discharge because of
her inability to be weaned from respiratory support. She
developed mild hypertension which was attributed to
cyclosporine. Her liver enzymes continue to decrease al-
though she has a persistently enlarged liver and spleen.
She has not had any recent fevers and has an age-appro-
priate neurologic exam. However, cognitive limitations
cannot be predicted. An unrelated HLA-matched donor
has been identified and she will be proceeding to bone
marrow transplant.
Discussion
Hemophagocytic lymphohistiocytosis is a potentially fatal
disease characterized by excessive macrophage and
lymphocyte activity. The onset of HLH in a susceptible in-
dividual typically follows either a documented or presumed
viral infection. Presently, HLH is often classified into pri-
mary (familial) and secondary (acquired) HLH.
The incidence of primary HLH is approximately
1:50,000 live born children [8]. However, HLH incidence
varies in clinical studies, most likely due to a difference in
prevalence across ethnic groups and/or emerging aware-
ness [9]. Although HLH often presents between birth and
18 months of age, onset in older age groups is possible and
has been shown to be a feature of particular gene mutations
[10]. Familial HLH has a median survival of less than 2
months after diagnosis if it remains untreated [9]. It is likely
that many cases are misdiagnosed as severe fatal infection.
In both primary and secondary HLH, Epstein Barr
virus is the most commonly identified inciting infection,
Figure 1 Hemophagocyte in bone marrow. Wright stain at 100x magnification. Macrophage with ingested nucleated red blood cells, nonnucleated
erythrocyte and a lymphocyte. Aspirate was taken the day after discontinuation of anakinra.
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herpes virus 8, influenza, parvovirus, enterovirus and
human immunodeficiency virus have also been described
[11]. In secondary HLH, associated malignancies include
neuroblastoma, Non-Hodgkin’s lymphoma and Langer-
hans’ cell histiocytosis.
Macrophage activation syndrome (MAS) can be con-
sidered a form of secondary HLH syndrome associated
with autoimmune disease. MAS complicates an estimated
10% of Systemic Juvenile Idiopathic Arthritis (sJIA) cases
[12], and approximately 1-5% of Systemic Lupus Erythema-
tosus (SLE) cases [13]. Clinical features of MAS similar to
primary HLH include high unremitting fever, hepatosple-
nomegaly, hepatic dysfunction, lymphadenopathy, enceph-
alopathy, cytopenia, elevated ferritin and coagulopathy
[12,14]. Laboratory similarities include depressed natural
killer (NK) cell cytotoxic function, elevated soluble IL-2 re-
ceptor levels and soluble CD163. In its early stages, MAS
can be a diagnostic challenge due to the overlap of symp-
toms with the underlying autoimmune disease. Factors po-
tentially differentiating HLH from MAS include: 1.) change
from quotidian to persistent fever pattern; 2.) sudden
change from cytosis to cytopenia; 3.) coagulopathy; and 4.)
decreasing ESR. Preliminary diagnostic criteria have been
examined for MAS in sJIA, which may help to improve
diagnosis of this condition in these patients [13,15].
As mentioned before, HLH is diagnosed through clear
clinical criteria. Despite awareness of the diagnostic cri-
teria, HLH diagnosis can be challenging because of the
variability in presentation. Symptoms, especially if infec-
tion associated, may spontaneously remit [3]. Individual
diagnostic criteria can be observed at distinct points inthe disease course and can also remit and recur. More-
over, many of the criteria are non-specific for HLH,
making it a diagnosis of exclusion in many cases. Finally,
criteria such as NK cell function and genetic testing can
take weeks to be finalized. Given all these challenges, it
is important to consider HLH as a diagnosis both at
onset and in the early stages of the disease process. In a
review of familial and acquired HLH, key laboratory
findings in establishing a diagnosis were identified as
negative or decreased NK function as well as elevated
soluble CD25 levels in all patients [16], suggesting these
studies must be evaluated early on in the clinical course.
In some centers, CD107a upregulation, a marker of NK
cell degranulation is used as a surrogate for NK cell
cytotoxicity [17]. However, as depressed NK cell cytotox-
icity is seen in many conditions secondary to inflamma-
tion or immunosuppressive factors, other symptoms
must be considered. Fever and splenomegaly occur in
approximately 70% of HLH patients [16]. Fevers may be
protracted, variable and may even resolve spontaneously.
About 50% of patients initially present with elevated tri-
glycerides, high ferritin, high LDH and/or a combination
of anemia, neutropenia and thrombocytopenia [8,16]. Of
note, ferritin is rarely> 200 μg/L in pediatric patients
with infections outside of the context of HLH [16] and
levels higher than this should raise suspicion for HLH.
Lastly, hemophagocytosis is seen in less than 40% of
patients at onset but is present in >80% of patients at
time of diagnosis [16].
There are presently five types of familial HLH (FHL)
[9], all of which impair the lytic activity of cytotoxic lym-
phocytes. Specifically, cytotoxic lymphocytes mediate
Figure 2 Levels for absolute neutrophil count (a.), platelet
count (b.) and ferritin (c.) in association with anakinra trial. The
horizontal axis in each figure indicates time in days from admission.
The orange triangles indicate the first and last day that daily
anakinra was given. In Figure 2a and 2b the red line denotes the
threshold below which diagnostic criteria is met for HLH while in
Figure 2c this line denotes the threshold above which HLH criteria is
met.
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gerous by secreting preformed destructive molecules
contained within specialized organelles termed lytic
granules [2]. In order to mediate cytotoxicity, lytic gran-
ules must contain appropriate effector molecules and belocalized to the contact site with the cell targeted for de-
struction. Once localized to that intercellular interface,
the lytic granules dock at the cell membrane. The mem-
brane of the granule and the cytotoxic lymphocyte are
fused, allowing the release of the lytic effector molecules
onto the targeted cell.
Familial HLH type 1 (FHL1) is linked to chromosome
9q21, but the exact gene remains unknown [9]. Perforin
(PRF-1) was the first identified FHL gene (located on
chromosome 10q21–22), and is responsible for familial
HLH type 2 (FHL2).
Perforin protein is an effector molecule found in lytic
granules. Once secreted, perforin inserts into the mem-
brane of the target cell and facilitates the uptake of gran-
zyme B and other cytolytic molecules contained in the
lytic granules, into the target cell to induce cell death
[1,9].
In perforin-deficient mice infected with high doses of
lymphocytic choriomeningitis virus (LMCV), haemopha-
gocytic lymphohistiocytosis could be induced, similar to
human FHL [18]. This suggests that failure to clear virus
will lead to persistence of viral antigens and prolonged
CD8 T cell activation and cytokine production. Other ani-
mal model studies demonstrate perforin’s role in regulat-
ing lymphocyte number in autoimmunity [19], after
microbial infection [20] and when other cell-death path-
ways are impaired [21]. The extent that these mechanisms
are involved in the control of immune responses, however,
is still speculative.
PRF-1 mutations account for approximately 20-40% of
FHL cases. It is important to note however that CD107a
up-regulation is usually normal in FHL2 as CD107a
represents a measure of degranulation [22].
FHL3 is caused by mutations in the UNC13D gene
located on chromosome 17q25. UNC13D encodes the
protein MUNC 13–4. Found on the surface of lytic gran-
ules, MUNC 13–4 is required for priming the lytic gran-
ules for docking at the cytotoxic cell membrane [9,12].
FHL 4 is caused by mutations in STX11 on chromosome
6q24 that encodes the syntaxin 11 protein. Syntaxin-11
is a member of the SNARE protein family and facilitates
the fusion of the lytic granule membrane with that of
the cytotoxic lymphocyte [1,23]. FHL5 is caused by
mutations in MUNC 18–2 located on chromosome
19p13. MUNC 18–2 encodes the syntaxin binding pro-
tein 2. It is a partner of syntaxin 11 and is required for
SNARE complex-mediated fusion of the lytic granule
with the cytolytic cell membrane [9,22].
In addition to genetic defects associated with FHL,
there are also immunodeficiency syndromes associated
with HLH that impair the secretion of lytic granule con-
tents. These include Griscelli syndrome type 2, Hermansky
Pudlak type II, Chediak Higashi and X-linked lymphoproli-
ferative disease Type 1. Griscelli syndrome type 2 and
Figure 3 Comparison of CD163 immunohistochemical stain of bone marrow one month before trial of anakinra trial (3a), and the day
after discontinuation (3b). Shown at 40x magnification. CD163 is an immunohistochemical stain that is specific for monocytes and
macrophages and the positive cells show brown surface staining. Prior to anakinra, there are slit-like macrophages and some with a few ingested
cells (blue arrow). On repeat biopsy and stain done after anakinra, there is an increase in the number of macrophages and the CD163 stain
demonstrates numerous hemophagocytic macrophages containing multiple ingested cells (blue arrows).
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binism due to an effect upon melanocyte pigment secre-
tion. Griscelli syndrome type 2 is identified by mutations in
RAB27A while Chediak Higashi syndrome is associated
with LYST mutations. Mutations of both these gene impair
proteins important for formation and/or trafficking of
secretory lysosomes [24]. In these syndromes, a gene defect
interferes with lytic granules reaching the cytotoxic
lymphocyte membrane, thus leading to impaired NK cell
cytotoxicity. Patients with X-linked lymphoproliferative dis-
ease have difficulty clearing Epstein-Barr virus (EBV)
infected B-cells, with subsequent extensive lymphocytic ex-
pansion into multiple organs. The SH2D1A mutation,
which encodes for the signaling lymphocyte activation mol-
ecule (SLAM)-associated protein SAP, is identified in XLP1.
Impaired cytolytic function in XLP1 is thought to cause ac-
cumulation EBV-infected B cells and persistence of reactive
inflammatory cells, which combine to produce an exagger-
ated immune response [25].
Treatment for HLH is described in the HLH 2004
revised guidelines [14] and is divided into acute and
long-term management. Initial treatment with an immu-
nomodulatory regimen is recommended. Patients with
primary HLH who fail to reach disease resolution within
8 weeks of treatment should continue on this regimen
for an additional treatment course. Hematopoetic stem
cell transplantation should be pursued as soon as a suit-
able donor is available for all patients with primary
HLH, relapsed HLH, or those failing to progress on ther-
apy [4]. There is no standard for the treatment of sec-
ondary HLH or MAS in the context of rheumatologicdisease. High dose corticosteroids, biologic agents,
cyclosporine and high dose intravenous immunoglobulin
have been used with varying success. Anakinra, a recom-
binant IL-1 receptor antagonist, has been increasingly
used for sJIA patients with MAS [24]. If initial treatment
fails, HLH salvage therapy may be pursued according to
the HLH 2004 chemotherapeutic regimens [14,12]. Con-
firmation of a genetic mutation is not needed for imme-
diate management but is important in differentiating
familial HLH and secondary HLH for long-term patient
management and family genetic counseling.
While anakinra has been successfully utilized in MAS,
it has not been formally studied in HLH associated with
bonafide mutations. In our patient with two identified
UNC13D mutations, anakinra was utilized as an immu-
nomodulator while the diagnosis was evolving. Although
the progression of our patient’s disease was not florid
while receiving anakinra, there were decreased platelet
and neutrophil counts during therapy. However, when
anakinra was stopped, there was a clear surge in ferritin
levels. It is unclear from our experience if anakinra mag-
nifies certain abnormalities found in primary HLH while
moderately quelling others. A more likely explanation is
that the anakinra functioned in partially blocking the
HLH-associated inflammation in our patient thus allow-
ing for the masking of certain phenotypic associations of
HLH such as ferritin, but not others (i.e., platelet
counts). While we were not situated to immunologically
prove the partial blockade of inflammation in our patient
while receiving anakinra, our experience suggests that its
use be reserved for the more mild secondary forms of
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more wide-ranging immunosuppression such as that
provided through the HLH-2004 protocol [4,14].
Conclusion
HLH is a clinical syndrome that remains difficult to diag-
nose. Our patient’s case demonstrates that use of im-
munosuppressive agents can cloud diagnosis. As
clinicians, it is important to be aware of this in order to
avoid delay in diagnosis and life-saving therapy.
Consent
“Written informed consent was obtained from the par-
ent of the patient for publication of this Case Report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.”
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